Myelodysplastic Syndromes

Our specialists provide expert care for people with myelodysplastic syndromes (MDS). These are conditions in which the blood-forming cells in the bone marrow are damaged, leading to a decreased number of red blood cells, white blood cells, or platelets. We use sophisticated testing to identify the type of MDS and determine the risk of the condition progressing. Then, we create a personalized and evidence-based treatment plan to meet your needs, ranging from watchful monitoring to stem cell transplantation.

Clinical Trials and Research Studies

Phase 6

A Multi-center Open-label Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years with Newly-diagnosed Philadelphia-negative ALL

Learn More

Phase 3

AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Learn More

Phase 1

A Phase 1 Open-label Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Learn More

Phase 3

A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Learn More